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Abstract Bioresorbable scaffolds (BRS) represent a novel
approach in coronary stent technology. In contrast to the
metallic stents, they provide transient scaffolding, thereby
safeguarding early vessel patency and acute gain. Subse-
quently a process of “decomposition” occurs, that results in
the complete absorption of the scaffold. This reduces the
risk of late complications, allowing the vessel to maintain its
integrity and physiological function. This unique ability has
attracted interest and nowadays several BRS are available.
The aim of this review article is to describe the advances in
the field, present the evidence from the preclinical and
clinical evaluation of these devices, and provide an over-
view of the ongoing clinical trials that were designed to
examine the effectiveness of BRS in the clinical setting.
Keywords Coronary artery disease . Stents . Bioresorbable
scaffolds . Vascular restoration therapy
Introduction
Bioresorbable scaffolds (BRS) have been heralded as the
fourth revolution in interventional cardiology as they intro-
duce a novel concept in the treatment of coronary artery
disease. These devices have the unique ability to permit the
restoration of vascular physiology and integrity as they
provide a temporary scaffold that is necessary to maintain
the patency of the vessel after intervention, and then they
gradually dissolve, liberating the vessel from its cage [1•, 2,
3]. Thus, it is expected that BRS will potentially overcome
the limitations of the traditional stents, such as the risk of
late stent thrombosis, neoatherosclerosis, and the local in-
flammation caused by the presence of a foreign body [4, 5].
In addition, BRS will allow a potential surgical revascular-
ization of the treated segment whereas traditional stents
often preclude this option.
The potential unique advantages of this rapidly developing
technology have lead to a drive towards the development of
several types of BRS by industry. Hence, today numerous
scaffolds are available with different compositions (eg, metal-
lic alloy or polymer), strengths, and weaknesses (Fig. 1).
Some of these are under development, some undergoing pre-
clinical evaluation, while others have already been implanted
in humans. The aim of this review article is to describe the
advances in this field, present the evidence stemming from the
evaluation of available BRS, and provide a synopsis of the
ongoing clinical trials designed to examine the effectiveness
of these devices in the clinical arena (Table 1).
BRS Assessed in Clinical Setting
Igaki-Tamai Stent; the 1st BRS
The Igaki-Tamai stent (Kyoto Medical Planning Co, Ltd,
Kyoto, Japan) is the first BRS implanted in humans. It is made
of poly-L-lactic acid (PLLA) monofilament and does not
contain any antiproliferative drug. The scaffold has a zig-zag
helical coil design with 2 radiopaque markers at the proximal
and distal end of the stent. Initially, stent implantation required
an 8F guide catheter and was performed using heated angio
contrast media at 80 °C. In vitro experiments have shown that
the device expands by itself to its original size within 0.2
seconds when it is heated to 70 °C, while at a human’s
temperature stent expansion takes 20 minutes.
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The Igaki-Tamai stent was implanted for the first time in
1998, and in 2000 a report was published that demonstrated
the feasibility and effectiveness of the device [6]. Fifteen
patients (19 lesions) were successfully treated with 25 scaf-
folds. Coronary angiography and intravascular ultrasound
(IVUS) performed the day after device implantation revealed
the absence of significant recoil. There was only 1 target
lesion revascularization (TLR) at 6 months follow-up. Quan-
titative coronary angiography (QCA) performed at 3 and
6 months demonstrated a mean diameter stenosis of 33±
14 % and 33±18 %, respectively. IVUS examination showed
that at 3 months the stent area increased and the lumen area
decreased (from 7.42±1.51 mm2 to 8.18±2.42 mm2 and from
7.42±1.51 mm2 to 5.67±2.42 mm2, respectively) but they did
not further change at 6 months follow-up (stent area: 8.13±
2.52 mm2; lumen area: 5.63±2.70 mm2).
Recently, Nishio et al reported the long term outcomes
(>10 years) after the implantation of the Igaki-Tamai stent
[7••]. In this study 50 patients (63 lesions) were treated with
84 BRS. One sub-acute scaffold thrombosis occurred during
hospitalization and was attributed to discontinuation of the
antiplatelet treatment due to an acute hemorrhagic gastric
ulcer. At 10 years follow-up 7 deaths (1 of unknown cause
and 6 due to noncardiac causes) and 3 additional myocardial
infarctions (MI) were reported (1 lesion related and 2 non-
lesion related). The TLR rate was 28 % (14 cases). The late
lumen loss (LLL) was 0.91±0.69 mm at 6 months, but
improved to 0.67±0.45 mm at 1 year and was only 0.59±
0.50 mm at 3 years follow-up. Grayscale serial IVUS ex-
amination performed in 18 patients showed that the mini-
mum lumen area decreased at 6 months (from 6.19±
2.26 mm2 postprocedure to 4.23±1.82 mm2), and then
increased (4.95±1.79 mm2) at 3 years follow-up. Converse-
ly, the scaffold area increased at 6 months and at 1 year
follow-up (from 7.63±2.69 mm2 postprocedure to 8.13±
2.63 mm2 at 6 months and 7.95±2.65 mm2 at 1 year), with
the scaffold no longer detectable after 3 years. Echogenicity
analyses of the serial IVUS data was performed in 13
Fig. 1 Developed BRSs. (a) Absorbable metallic stent (AMS) 1, (b)
AMS 2, (c) drug-eluting AMS (DREAMS) 1, (d) DREAMS 2, (e)
Igaki-Tamai stent, (f) Abbott Vascular BRS 1.0, (g) Abbott Vascular
BRS 1.1 and chemical structure of the PLLA, (h) Reva Medical BRS
revision 1, (i) molecular composition of the Reva Medical BRS and (j)
second revision of the REVA Medical BRS, (k) DeSolve BRS, (l) ART
BRS, (m) first and second generation IDEAL scaffold and chemical
structure of the polymer used, (n) Acute BRS, (o) Amaranth PLLA, (p)
Xinsorb, and (q) Sahajanand BRS. The images for the Igaki-Tamai
stent and for the IDEAL biostent were reprinted by permission of
Lippincott Williams & Wilkins from: Circulation. 2011;123:779-97
[34], while the image for the Sahajanand BRS was reprinted by
permission of Edizioni Minerva Medica from: Minerva Cardioangiol.
2009;57:537–65 [18]
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lesions, and showed a significant increase in the echogenic-
ity of the scaffolded vessel after device implantation, with a
progressive reduction in echogenicity at 1 year, and return-
ing to the pre-implantation values at 3 years follow-up,
thereby indicating complete resorption of the scaffold.
Although the abovementioned results were promising,
the device failed to progress as it required a larger guide
catheter for implantation and heated contrast, the latter being
a potential cause of concern in causing local vessel wall
injury [8]. Kyoto Medical has recently improved the design
of the device, which can now be implanted through a 6F
guide catheter without the need for a heated contrast agent.
The second generation Igaki-Tamai stent is currently under-
going preclinical evaluation in Germany.
Magnesium Metallic Stent
The absorbable metallic stent (AMS) (Biotronik, Berlin,
Germany) is composed of magnesium and rare earth metals,
and is the only bioresorbable metallic stent implanted in
humans. The device has a high mechanical strength and
similar properties to the other metallic stents. Experimental
studies have demonstrated that it has antithrombotic prop-
erties attributed to the electronegative charge produced dur-
ing the degradation of the device [9]. The majority of the
resorption process is completed within 2 months and pro-
duces inorganic salts without causing significant inflamma-
tory response [10].
The feasibility and efficacy of the first generation AMS
(AMS 1) was examined in the PROGRESS AMS trial. Sixty
three patients with a single de novo lesion were included
and received 71 scaffolds. There was a high incidence of
TLR (45 %) at 12 months and an increased LLL on angio-
gram performed at 4 months follow-up (1.08±0.49 mm). At
this time point, the vasomotor function was assessed in 5
treated segments and appeared restored [11]. IVUS at
4 months follow-up showed almost complete resorption of
the device and a significant reduction in luminal dimen-
sions. Forty five percent of this reduction was attributed to
neointima formation, 42 % to negative remodeling, and
13 % to an increase in the plaque area outside the stent.
The negative remodeling was attributed to an early reduc-
tion of the scaffold’s radial force that was due to the fast
resorption of the device. Thus, the AMS 1 was modified
using a different magnesium alloy, which provided in-
creased radial strength and prolonged the duration of the
resorption process. Preclinical evaluation in animal models
confirmed the effectiveness of the second generation AMS
[12]. Before being implanted in humans, the device under-
went further modifications with the incorporation of pacli-
taxel elution and a biodegradable matrix that could control
the release of the antiproliferative drug (AMS 3). The drug-
eluting AMS (DREAMS) was tested in clinical setting in theTa
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BIOSOLVE-I study. In this prospective, multi-center, first-
in-man trial, 46 patients with a single de novo lesion with a
reference diameter between 3.0–3.5 mm were included.
Forty seven DREAMS were successfully implanted. The
TLR rate at 6 months was 4.3 %, and no other cardiac
events were reported. The LLL was 0.64±0.50 mm at this
time point. A restoration of vessel geometry was also noted
at 6 months, with the angulation of the treated segments
reported to increase from 14.9±12.0° immediately postpro-
cedure to 26.1±15.9° at late follow-up (lesion angulation at
baseline: 31.4±21.2°) [13].
DREAMS was further modified to create the next genera-
tion DREAMS. DREAMS 2 has radiopaque markers at both
ends (made from tantalum) and sirolimus elution instead of
paclitaxel. Preclinical evaluation of the device in porcine
models demonstrated a better endothelization and reduced
inflammation in the first 2 months post-implantation compar-
ing to DREAMS 1. The device has not yet been implanted in
humans [14].
Abbott Vascular BRS
The Abbott Vascular BRS (Abbott Vascular, Santa Clara,
CA, USA) is made from semicrystalline PLLA coated with
the amorphous poly-D, L-lactide (PDLA) polymer, which
contains and controls the release of the antiproliferative drug
everolimus. Device degradation requires 2–3 years and
includes hydrolysis of the PLLA and PDLA. The outcome
of this process is the formation of small molecules of lactic
acid which are phagocytosed by macrophages when their
diameter becomes <2 μm. The resorption is completed with
the catabolism of these molecules in the Krebs cycle.
The first Abbott Vascular BRS device (revision 1.0) was
investigated in humans in the ABSORB Cohort A study. In
this single-arm, prospective, open-label study, 30 patients
with single de novo coronary artery disease and stable or
unstable angina were enrolled [15]. During the follow-up
period, there was only 1 non-Q wave MI, while the reported
LLL was 0.43±0.37 mm at 6 months and 0.48±0.28 mm at
2 years. The vasomotor function was restored at 2 years
[16]. IVUS examination at 6 months revealed scaffold
shrinkage (from 6.94±1.70 mm2 to 6.29±1.47 mm2) which
appeared to be affected by the composition of the plaque
and was more intense in fibrofatty and lipid rich lesions
[17]. To overcome this drawback, the BRS was re-designed.
The improved revision, 1.1, had a different design with its
struts having an in-phase hoop, with straight links arrange-
ments to provide to the scaffold an increased radial support.
In addition, the polymer in the updated version was pro-
cessed in such a way so as to give the scaffold additional
mechanical strength [18].
The performance of the BRS 1.1 was tested in the AB-
SORB Cohort B study. This multicenter, single-arm trial
recruited 101 patients who had single or 2 vessel de novo
coronary artery disease. All patients were treated with a 3×
18 mm BRS. The studied population was divided into 2
groups. The first had invasive follow-up assessment (QCA,
IVUS, IVUS palpography, IVUS virtual histology, IVUS
echogenicity, and optical coherence tomography [OCT],
which was optional) at 6 months and at 2 years, and the
second group had similar assessments at 1 and at 3 years.
Computed tomographic coronary angiography (CTCA) was
performed in both groups at 18 months follow-up.
In group 1 there was only 1 TLR at 6 months, while the
LLL was 0.19±0.18 mm [19]. At 2 years the LLL was 0.27±
0.20 mm [20]. Follow-up IVUS examination demonstrated a
reduction in the mean lumen area at 6 months (6.60±
1.22 mm2 vs 6.37±1.12 mm2, P<0.005). Similar results were
reported in serial OCTexaminations performed in 23 patients:
the lumen was decreased at 6 months (7.23±1.24 mm2 vs
6.07±1.39 mm2, P<0.001) with no further changes at 2 years
(5.99±1.61 mm2, P00.26). On the other hand, the scaffold
area was reported to progressively increase during follow-up
(7.47±1.18mm2 at baseline, 7.70±1.34mm2 at 6 months, and
8.34±1.83 mm2 at 2 years) [19].
At the time of writing the invasive follow-up assessment
of group 2 has not yet been completed. The 1 year follow-up
results, which were recently published, are similar to those
reported in group 1. Two non-Q wave MI and 2 TLR
occurred within the first year, while the QCA showed a
LLL of 0.27±0.32 mm. OCT examination at 1 year demon-
strated a significant reduction in the lumen area and an
increase in the scaffold area [21].
Apart from the ABSORB Cohort B trial that it is
underway, 3 more studies have recently commenced: the
ABSORB Extend, the ABSORB Physiology, and the
ABSORB II. The ABSORB Extend is a worldwide
registry that aims to recruit 1000 patients with de novo
single or 2 vessel disease and report the safety and
efficacy of the device. In this registry a 2.5 mm BRS
was introduced thus, allowing for the examination of
the feasibility of a BRS in small vessels (reference
diameter between 2.0 mm and 3.3 mm). In addition,
patients with long lesions will be also included, and
hence we will be able to evaluate the potential safety
of overlapping devices. The ABSORB Physiology study
aims to assess the acute and long-term effect of a BRS
1.1 compared with a conventional metallic drug-eluting
stent, in terms of impact on coronary physiology. In this
randomized trial 36 patients will be included and will
be followed up for 2 years. The following variables will
be evaluated: vascular compliance, distensibility, endo-
thelial responsiveness (defined as change in vessel di-
ameter during pacing, hand grip, and acetylcholine
injection), and changes in the shear stress distribution,
after device/stent implantation, and at 2 years follow-up.
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The ABSORB II is a prospective, randomized control
trial that aims to compare the safety and efficacy of the
BRS 1.1 vs the Xience prime stent. Five hundred one
patients with stable angina and single or 2 vessel dis-
ease will be recruited and randomized on a 2:1 basis to
BRS 1.1 and Xience prime stent implantation. The
study has recently started and is expected to be com-
pleted by 2015.
Reva Medical BRS
The Reva Medical BRS (Reva Medical Inc, San Diego,
CA, USA) is a tyrosine poly (desamino tyrosyl-tyrosine
ethyl ester) carbonate radiopaque stent. The first revi-
sion had a unique slide and locking design that provid-
ed flexibility and strength, eliminated the device hinge
points and the polymer’s strain, and maintained the
acute lumen gain after device deployment. The resorp-
tion process includes hydrolysis of the polymer and is
completed between 18–24 months.
The performance of the device was examined extensively
in animal models with initial results proving promising [22,
23]. Hence, the company proceeded to conduct the first-in-
man trial, the RESORB study, which included 27 patients.
The immediate post-procedure results showed an increase in
the minimal lumen diameter from 0.88±0.39 mm to 2.76±
0.39 mm, suggesting excellent scaffold expansion. Follow-
up intravascular imaging revealed the absence of vessel
shrinkage (external elastic lamina: 15.5±4.0 mm2 at base-
line and 15.3±3.1 mm2 at follow-up). At 12 months there
was a high event rate with 18 reported TLR, 3 of which lead
to a non-Q wave MI [24]. These poor outcomes were
attributed to focal mechanical failures of the device.
Thus, the scaffold was re-designed resulting in the sec-
ond generation BRS. The updated ReZolve device had a
stronger resilient polymer and a novel slide and spiral lock
mechanism that provides better radial support and reduces
vessel recoil. The new scaffold has a better crossing profile,
can be implanted with the use of a 6F guide catheter (the
previous generation device required a 7F guide), and instead
of paclitaxel it has sirolimus elution. After successful pre-
clinical evaluation, the Rezolve BRS is undergoing clinical
evaluation in the RESTORE trial. This study aims to recruit
50 patients with de novo coronary artery disease and exam-
ine the safety and effectiveness of the new scaffold. The
recruitment started in December 2011, and the studied pop-
ulation will be followed for 5 years [25]. The primary and
secondary end-points are illustrated in Table 1. Apart from
the RESTORE trial, there is a plan for the conduction of a
further trial, the ReSolve CE Mark study, which is expected
to commence later this year. This trial aims to provide the
device with Conformité Européenne (CE) mark approval,
and will randomize 350 patients on a 2:1 basis to treatment
with the ReZolve BRS against a commercially available
metallic drug-eluting stent.
IDEAL BRS
The IDEAL (Xenogenics Corp, Canton, MA, USA) has
2 components: the backbone and the drug layer. The
backbone of the device is made from polylactide anhy-
dride mixed with a polymer of salicylic acid and seba-
cic acid linker, and is designed to provide radial
strength. The drug layer consists of salicylate that con-
trols the release of the antiproliferative drug sirolimus.
The presence of salicylic acid provides the device with
anti-inflammatory properties, which have been con-
firmed in preclinical studies [26]. The safety and the
efficacy of the scaffold were tested in humans in the
Whisper study. In this prospective, open label trial, 11
patients underwent BRS implantation and were
followed-up for 18 months. The results were reported
in EuroPCR in 2009 [27]. Although there was no scaf-
fold shrinkage, there was a reduction in lumen area due
to insufficient neointima suppression, which was attrib-
uted to inadequate drug dosing and to the rapid release
of the sirolimus elution.
The second revision of the IDEAL BRS has a higher drug
dose, a slower release rate, and in contrast to the first
generation device that required an 8F guide catheter, it can
be implanted through a 6F guide catheter. The device is
currently undergoing preclinical evaluation [28].
DeSolve BRS
DeSolve BRS (Elixir Medical, Sunnyvale, CA, USA) fea-
tures a fully bioresorbable polymer (PLLA-based) scaffold
that is coated with a PLLA-based resorbable polymer-drug
matrix. It contains 2 antiproliferative drugs: novolimus at a
dose of 5 mcg/mm and myolimus at a dose of 3 mcg/mm.
The device was evaluated for the first time in humans in the
DeSolve 1 study. Fifteen patients were enrolled in this
feasibility trial and underwent percutaneous coronary inter-
vention with the DeSolve BRS. Patients’ recruitment has
been completed and the 6 months follow-up has begun and
will be reported later this year. Preliminary follow-up imag-
ing results have shown low neointima hyperplasia and no
evidence of scaffold shrinkage [29]. In addition, the DeS-
olve NX study has recently commenced and aims to evalu-
ate the safety and effectiveness of the BRS in 150 patients.
The study design and the primary and secondary end-points
are shown in Table 1. There is also a plan in the pipeline for
the conduction of the DeSolve NX II pivotal trial that will
examine the safety and efficacy of the device in a broad
number of patients, so as to potentially acquire CE mark
approval.
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ART BRS
The ART BRS (Arterial Remodeling Technologies, Noisy le
Roi, France) is manufactured from a PLLA amorphous
polymer. The device does not have drug elution, is 6F
compatible, and provides vessel transient scaffolding for
5–7 months. Full resorption occurs within 18 months.
The performance of the BRS was compared with the
Multilink bare-metal stent (Abbott Vascular, Santa Clara,
CA, USA) in rabbit and porcine models. More than 250
devices were implanted. No MACEs were reported. The
LLL was higher in the ART group in the first weeks,
thereafter it began to decrease due to a “positive BRS
remodeling,” and at 3 months the LLL in the ART scaf-
fold was comparable to that observed in the Multilink
bare-metal stent [30]. In view of these promising results,
the company is currently designing the first-in-man study,
“ART-FIM CE Mark,” which aims to assess the safety and
feasibility of the device in humans and is expected to start
this year.
Amaranth
The Amaranth BRS (Amaranth Medical Inc, Mountain
View, CA, USA) is composed of a PLLA polymer and does
not contain an antiproliferative drug. The resorption process
takes approximately 1–2 years.
The device is currently undergoing preclinical evaluation.
The first results demonstrated that the BRS has excellent
deliverability and radial strength post deployment. The LLL
at 1, 3, and 6 months follow-up was similar in animals
receiving the Amaranth BRS and in animals implanted with
a Liberte bare-metal stent (Boston Scientific, Natwick, MA,
USA). At all time points, the neointima proliferation,
assessed by OCT, was smaller in the Amaranth BRS com-
pared with the Liberte. The company is planning to com-
mence this year the first-in-man study, which will include 30
patients and will compare the device with a commercially
available bare-metal stent.
Xinsorb BRS
The Xinsorb BRS (Huaan Biotechnology Group, Laiwu,
China) is made by PLLA and is covered by sirolimus
elution. The efficacy of the device has been recently exam-
ined in preclinical setting, and compared with the Excel
drug-eluting stent (JW Medical System, Weihai, China),
which has the same antiproliferative drug. In a small study
recently reported in Transcatheter Cardiovascular Therapeu-
tics 2011, 16 BRS, and 16 metallic stents were implanted in
porcine arteries. No difference in the percent area stenosis
(18.6±5.2 % vs 21.4±7.2 % and 24.5±4.7 % vs 27.7±
5.6 %, P>0.05) or in the inflammation score (0.84±0.15
vs 0.74±0.10 and 0.93±0.26 vs 0.88±0.10; P>0.05) were
reported between the 2 devices at 30 and 90 days follow-up
[31]. These preliminary results are promising; however,
further preclinical examination is necessary before conduct-
ing a first-in-man trial.
Acute BRS
The Acute BRS (Orbus Neich, Fort Lauderdale, FL, USA) is
different from the other BRS as it incorporates + CD34 anti-
bodies for endothelial progenitor cells capture, which are
expected to expedite the endothelial coverage of the BRS
[32]. The device also has sirolimus elution, while its backbone
is composed of 3 biodegradable polymers (poly-L lactic, poly-
D lactic, and poly-L-lactide-co-ε-caprolactone) which provide
the required radial strength. The device is currently undergo-
ing preclinical evaluation in porcine models. The first angio-
graphic and intravascular imaging results showed an optimal
device implantation without evidence of fracture [33]. An
interim update is expected at EuroPCR 2012.
Other BRSs
Apart from the abovementioned BRS there are several other
devices that are currently under development. These include
the Sahajanand BRS (Sahajanand Medical Technologies Pvt
Ltd, Surat, Gujarat, India), the Avatar BRS (S3V; Vascular
Technologies Pvt Ltd, Bangalore, Karnataka, India India),
the MeRes BRS (Meril Life Science, Vapi, Gujarat, India),
and the Zorion BRS (Zorion Medical, Indianapolis, IN,
USA). Detailed descriptions of these scaffolds are not yet
available.
Conclusions
BRS is a relatively new technology introduced to address the
limitations of the traditional metallic stents. It has been more
than 14 years since their first implantation in humans and
although there are several BRS available, these devices still
have limited applications. This paradox is due to the fact that
they have a totally different design and behavior that required
extensive study. Evidence from the validation of the second
generation BRS indicates that they have overcome the draw-
backs of the first generation (eg, rapid bioresorption and device
shrinkage) and that they are able to compete with the metallic
stents in terms of safety and efficacy. As to whether the dream
of a BRS becoming the “workhorse” intracoronary device of
the future remains to be answered from the ongoing and
upcoming clinical studies.
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